期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

良性前列腺增生的药物治疗现状 被引量：2

Effect of the Drugs in the Treatment of Benign Prostatic Hyperplasia
下载PDF
导出
摘要 良性前列腺增生（BPH）是中老年男性的常见病。目前，以5a-还原酶抑制剂及a-肾上腺素受体阻滞剂为主的药物治疗已经替代传统的经尿道前列腺切除术，成为多数BPH患者的治疗首选。本文就BPH的药物治疗现状作简要综述。 Benign prostatic hyperplasia （BPH） is the common disease in the elderly men. 5 -a reductase inhibitors and a adrenergic receptor blockaders have replaced transurethral prostateetomy and have been the first choice of the treatment methods of BPH. This paper reviews the effect of these drugs in the treatment of BPH.
作者 林碧玲 何国平
机构地区 中南大学护理学院 海南省农垦总医院
出处 《国际老年医学杂志》 2014年第3期139-142,共4页 International Journal of Geriatrics
关键词 良性前列腺增生 5a-原酶抑制剂 a-肾上腺素受体阻滞剂 药物治疗 Benign prostatic hyperplasia 5 - a reductase inhibitor a - adrenergic receptor blockaders Drug treatment
分类号 R697.32 [医药卫生—泌尿科学]
  • 相关文献

参考文献23

  • 1Hasan M, Parveen F, Shamsuzzaman AK, et al. Comparison of efficacy between Tamsnlosin and Finas- teride on symptomatic Benign Prostatic Hyperplasia [J]. Mymensingh Med J, 2007, 16 (2): 154- 159.
  • 2Kaplan SA, Roehrborn CG, McConnell JD, et al. Long - term treatment with finasteride results in a clini- cally significant reduction in total prostate volume com- pared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial [ J]. J Uro, 2008, 180 (3): 1030-1032.
  • 3Meconnel JD, Bruskewitz R, Walsh P, et al. The effect of finasterideon the risk of actue urinary retention and the need for surgical treatment among men with be- nign prostatic hyperplasia [J]. N Engl J Med, 1998, 338 : 557.
  • 4李宁忱,那彦群,丁强,张元芳,吴宏飞,杨宇如,鲁功成,郭应禄.新型5α-还原酶抑制剂爱普列特治疗良性前列腺增生的Ⅳ期临床研究[J].中华泌尿外科杂志,2002,23(7):413-416. 被引量：33
  • 5Issa MM, Runken MC, Grogg AL, et al. A large ret- rospective analysis of acute urinary retention and pros- tate--related surgery in BPH patients treated with 5 - alfha reductase inhibitors: dutasteride versus finastefide [J]. Am J Manag Care, 2007, 13 (Suppl 1): S10 - S16.
  • 6Fenter TC, Davis EA, Shah MB, et al. Dutastefide vs finastefide : assessment of diferences in acute urinary re- tention rates and surgical risk outcomes in an elderly population aged > or: 65 years [ J ]. Am J Manag Care, 2008, 14 (5 suppl2): s154-s159.
  • 7Tsukamoto T, Endo Y, Narita M. Assessment of rec- ommended dose of dutastefide on Japanese men with be- nign prostatic hyperplasia: a randomized, double - bhnd, placebo-controlled, parallel- group, dose re- sponse study [ J]. Hinyokika Kiyo, 2009, 55 (4) : 209 -214.
  • 8Roehrbom CG, Siami P, Barkin J, et al. The efects of combination thempy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4 -year results from the CombAT study [J]. Eur Urol, 2010, 57 (1): 123-131.
  • 9Van Kerrebroeek P. Long - term safety and efficacy of a oncedaily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open label extension study[J]. Eur Urol, 2002, 41:54-60.
  • 10MeVary HT. Alfuzosin for symptomatic benign prostat- ic hyperplasia: long - term experience [ J]. J Urol, 2006, 175 (1): 55.

二级参考文献3

共引文献32

同被引文献8

引证文献2

二级引证文献4

国际老年医学杂志
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部